GNH USA

Europe — EMA

Moniyot-131 T (Sodium Iodide (131i))

GNH USA supplies Moniyot-131 T (Sodium Iodide), a radioactive iodine for thyroid imaging and treatment of hyperthyroidism. Request a quote for global supply.

Sodium Iodide (131i)

Request sourcing

1
Pack/s

What is Sodium Iodide (131i)?

Sodium Iodide (I-131), the active ingredient in Moniyot-131 T, is a radioactive iodine presented as an oral radiopharmaceutical for diagnostic and therapeutic use. It is selectively taken up by thyroid tissue, enabling imaging of thyroid function and, at therapeutic levels, ablation of hyperfunctioning thyroid cells in patients with thyroid disorders.

GNH USA supplies Moniyot-131 T as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies across global markets. All shipments meet regulatory requirements for radioactive materials.

What is Sodium Iodide (131i) used for?

Moniyot-131 T is a radioactive iodine agent that acts on thyroid tissue for both diagnostic and therapeutic purposes. - Thyroid imaging: enables scintigraphic visualization of iodine uptake to assess gland function. - Hyperthyroidism: delivers therapeutic radiation to ablate overactive thyroid tissue, reducing hormone production. - Thyroid cancer follow‑up: used in certain protocols to detect residual or metastatic disease after surgery.

What are the side effects of Sodium Iodide (131i)?

Sodium Iodide (I‑131) may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring shortly after ingestion. - Salivary gland soreness: transient discomfort due to iodine uptake. - Dry mouth: reduced salivary flow. - Taste alteration: metallic or altered taste perception. - Mild fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Thyroiditis: inflammation of the thyroid gland. - Severe radiation‑induced thyroid dysfunction: hypothyroidism or exacerbated hyperthyroidism. - Bone marrow suppression: decreased blood cell counts. - Allergic reaction: rash, itching, or anaphylaxis in rare cases.

What precautions apply to Sodium Iodide (131i)?

When using Sodium Iodide (I‑131), several precautions should be observed to ensure patient safety and regulatory compliance. - Pregnancy: avoid use unless benefits outweigh risks, as radiation may affect fetal thyroid. - Breastfeeding: discontinue breastfeeding for a period recommended by the treating physician. - Thyroid status: assess baseline thyroid function before administration. - Radiation safety: follow local guidelines for handling and patient isolation to limit exposure to others. - Drug interactions: review concomitant medications that may alter iodine uptake. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

What does Sodium Iodide (131i) interact with?

Sodium Iodide (I‑131) can interact with other agents that influence iodine kinetics or radiation effects.

Major Interactions (Avoid): - Antithyroid drugs (e.g., propylthiouracil, methimazole): reduce iodine uptake, diminishing efficacy. - Lugol’s solution or potassium iodide: saturate the thyroid, preventing radioiodine accumulation. - High‑dose corticosteroids: may alter radiation response and increase risk of side effects.

Moderate Interactions (Monitor Closely): - Lithium: can increase radioiodine retention in the thyroid. - Amiodarone: contains iodine and may interfere with radioiodine distribution. - Diuretics: affect renal clearance of iodine, potentially modifying exposure.

Frequently asked questions

What is Moniyot-131 T used for?+
Moniyot-131 T contains sodium iodide (I‑131) and is employed as a radioactive iodine radiopharmaceutical. It is used primarily for diagnostic imaging of thyroid function (thyroid scintigraphy) and for therapeutic ablation of hyperfunctioning thyroid tissue in conditions such as hyperthyroidism. The product enables clinicians to visualize iodine uptake in the gland and, when administered at therapeutic activity, to reduce excess hormone production.
How does Sodium Iodide (I‑131) work?+
Sodium Iodide (I‑131) is taken up by thyroid follicular cells via the sodium‑iodide symporter. Once inside the gland, the radioactive iodine emits beta particles that cause localized cellular damage, and gamma photons that can be detected by a gamma camera. This dual action provides both imaging capability and, at higher doses, therapeutic destruction of overactive thyroid cells.
What is the usual dose of Moniyot-131 T?+
The dose of Moniyot-131 T is determined individually by the prescribing physician based on the intended diagnostic or therapeutic purpose, the patient’s thyroid status, and regulatory guidelines. Dosage calculations consider the required radioactivity (measured in megabecquerels) and patient-specific factors. Clinicians set the exact amount to ensure optimal imaging quality or therapeutic effect while minimizing radiation exposure.
Is Moniyot-131 T safe during pregnancy or breastfeeding?+
Radioactive iodine can cross the placenta and enter breast milk, potentially affecting fetal or neonatal thyroid development. Consequently, Moniyot-131 T is generally avoided in pregnant or breastfeeding women unless the clinical benefit clearly outweighs the risk. If use is unavoidable, the prescribing physician will implement strict radiation safety measures and may advise temporary cessation of breastfeeding for a defined period.
How do I order Moniyot-131 T from GNH USA?+
To place an order, visit the product page on gnh-usa.com and submit an enquiry with the required quantity of Moniyot-131 T. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team then confirms pricing, availability, shipping conditions (including any required radiation handling) and assists with import documentation.
How does Moniyot-131 T compare with other thyroid radiopharmaceuticals?+
Moniyot-131 T delivers iodine‑131, which provides both diagnostic gamma emission and therapeutic beta radiation. Compared with iodine‑123, which emits only gamma photons, I‑131 enables combined imaging and treatment but involves higher radiation dose. Iodine‑131 is also distinct from non‑radioactive antithyroid drugs, offering a targeted ablative approach rather than systemic hormone synthesis inhibition. Choice of agent depends on clinical goals, required radiation dose, and regulatory considerations.
What are the storage and handling requirements for Moniyot-131 T?+
Moniyot-131 T should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. The product must be protected from moisture, light, and physical damage. Because it is a radioactive material, handling should follow local radiation safety regulations, including use of appropriate shielding, labeling, and disposal procedures. Facilities must maintain a secure inventory and limit exposure to personnel and the public.
How is Moniyot-131 T administered?+
Moniyot-131 T is administered orally, typically as a single dose in liquid or capsule form, depending on the specific product presentation. The patient swallows the dose with water under the supervision of a qualified healthcare professional. After ingestion, the patient may be instructed to follow radiation safety precautions, such as limiting close contact with others for a prescribed period, to reduce unnecessary radiation exposure.
What are the most serious risks associated with Moniyot-131 T?+
The most serious risks include radiation‑induced thyroiditis, severe hypothyroidism or exacerbated hyperthyroidism, and bone marrow suppression leading to cytopenias. In rare cases, allergic reactions or anaphylaxis may occur. Long‑term exposure carries a small risk of secondary malignancies due to ionizing radiation. Patients should be monitored closely for signs of these complications, and any adverse symptoms should be reported to the treating physician promptly.
Who should not use Moniyot-131 T?+
Moniyot-131 T is contraindicated in individuals with known hypersensitivity to iodine or sodium iodide, in pregnant women unless absolutely necessary, and in breastfeeding mothers who cannot suspend nursing. Patients with uncontrolled thyroid disorders that require alternative management, or those who cannot comply with radiation safety guidelines, should also avoid its use. The prescribing clinician must evaluate each patient’s medical history and current condition before deciding on therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sodium Iodide (131i)
Route
Oral Use
Manufacturer
Monrol Europe Srl
Origin
EU

Related products

Fid-Na

Fid-Na

Sodium Iodide (131i)

Fidelio Farm
EU
Iodeto De Sódio (131i) Ge Healthcare

Iodeto De Sódio (131i) Ge Healthcare

Sodium Iodide (131i)

Ge Healthcare Buchler Gmbh & Co. Kg
EU
Iodeto De Sódio [i 131] T Curium Netherlands

Iodeto De Sódio [i 131] T Curium Netherlands

Sodium Iodide (131i)

Curium Netherlands B.V.
EU
Iodopol

Iodopol

Sodium Iodide (131i)

Narodowe Centrum Badań Jądrowych
EU